Loading...
OTCM
KRBPQ
Market cap94kUSD
Jun 09, Last price  
0.04USD
Name

Kiromic Biopharma Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
188.99%
Rev. gr., 5y
%
Revenues
0k
Net income
-27m
L+26.32%
-3,815,700-3,750,400-19,203,500-25,654,300-38,181,200-21,294,000-26,898,000
CFO
-19m
L-8.33%
-2,152,900-2,913,900-6,126,600-20,321,500-23,745,900-21,225,300-19,458,000
Earnings
Aug 07, 2025

Profile

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
IPO date
Oct 16, 2020
Employees
31
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
15,707
19,939
33,182
Unusual Expense (Income)
NOPBT
(15,707)
(19,939)
(33,182)
NOPBT Margin
Operating Taxes
3,450
Tax Rate
NOPAT
(15,707)
(19,939)
(36,632)
Net income
(26,898)
26.32%
(21,294)
-44.23%
(38,181)
48.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
659
BB yield
-69.02%
Debt
Debt current
1,370
14,631
4,952
Long-term debt
14,609
2,454
6,588
Deferred revenue
Other long-term liabilities
(228)
Net debt
14,842
13,881
10,894
Cash flow
Cash from operating activities
(19,458)
(21,225)
(23,746)
CAPEX
(366)
(207)
(4,880)
Cash from investing activities
(366)
(207)
(4,866)
Cash from financing activities
18,415
23,991
3,903
FCF
1,703
(22,728)
(36,614)
Balance
Cash
1,137
3,204
645
Long term investments
Excess cash
1,137
3,204
645
Stockholders' equity
(149,793)
(122,896)
(101,947)
Invested Capital
138,804
129,317
105,583
ROIC
ROCE
142.93%
EV
Common stock shares outstanding
26,069
1,098
545
Price
0.90
3.45%
0.87
-83.95%
5.42
-88.19%
Market cap
23,462
2,356.92%
955
-67.65%
2,952
-83.10%
EV
38,304
14,836
13,846
EBITDA
(13,473)
(17,718)
(31,508)
EV/EBITDA
Interest
3,723
1,852
166
Interest/NOPBT